Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$4.16 USD
+0.17 (4.26%)
Updated May 24, 2024 04:00 PM ET
After-Market: $4.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GLUE 4.16 +0.17(4.26%)
Will GLUE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLUE
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
Other News for GLUE
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Monte Rosa Therapeutics presents data at DDW 2024 on MRT-6160
Monte Rosa Therapeutics prices $100M stock and warrants offering
SPIR, ADTH and AWIN among pre-market losers